Title: Christophe D Guillon: Innovator in Vasopressin Receptor Antagonism
Introduction
Christophe D Guillon is a notable inventor based in the United States. He has made significant contributions to the field of pharmacology, particularly in the development of novel compounds targeting the vasopressin V1a receptor. His work is essential for advancing treatments for various disease states.
Latest Patents
Christophe D Guillon holds a patent for "Beta-Lactamyl Vasopressin V1a Antagonists." This patent describes novel 2-(azetidin-2-on-1-yl)alkanedioic acid derivatives and 2-(azetidin-2-on-l-yl)alkoxyalkanoic acid derivatives. These compounds are designed for use in treating conditions responsive to antagonism of the vasopressin V1a receptor. Although he currently has 0 patents, his research is pivotal in the pharmaceutical industry.
Career Highlights
Guillon is associated with Azevan Pharmaceuticals, Inc., where he continues to innovate in drug development. His expertise in pharmacology and receptor antagonism has positioned him as a valuable asset in the field. His work is characterized by a commitment to improving therapeutic options for patients.
Collaborations
Some of his notable coworkers include Robert F Bruns and Ned D Heindel. Their collaborative efforts contribute to the advancement of research and development in the pharmaceutical sector.
Conclusion
Christophe D Guillon is a dedicated inventor whose work in vasopressin receptor antagonism holds promise for future medical advancements. His contributions to Azevan Pharmaceuticals, Inc. and the broader field of pharmacology are noteworthy.